Kodu・Aktsiate loetelu・Bio-Techne Corp

Bio-Techne Corp

Suletud

SektorTervishoid

72.38 -0.06

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

72.26

Max

72.43

Põhinäitajad
By Trading Economics
Sissetulek	3.6M 55M
Müük	9.8M 321M
P/E Sektori keskmine	62.302 56.432
Aktsiakasum	0.49
Dividenditootlus	0.44
Kasumimarginaal	17.006
Töötajad	3,000
EBITDA	-6.7M 92M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+0.87% upside

Dividendid
By Acuity
Dividenditootlus Sektori keskmine	0.44% 2.27%
Järgmine tulemuste avaldamine	4. nov 2026
Järgmine dividendimakse kuupäev	27. nov 2026
Järgmine aktsia dividendi kuupäev (ex-date)	16. nov 2026

Turustatistika
By TradingEconomics
Turukapital	96M 11B
Eelmine avamishind	72.44
Eelmine sulgemishind	72.38

Uudiste sentiment

By Acuity

50%

120 / 339 Pingereas Healthcare

Bio-Techne Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2026, 19:47 UTC

Correlated Moves

Bio-Techne Corp shares are lower today, reflecting a decline since Friday. Agilent Technologies' drop may be influencing Bio-Techne's performance amid inflation data focus.

28. aug 2026, 19:46 UTC

Correlated Moves

Bio-Techne Corp is trading lower today, reflecting a broader decline in the biotech sector, including Charles River Laboratories International Inc.

27. aug 2026, 23:31 UTC

Bio-Techne Corp shares are higher in after-market hours, though no specific news was identified. Recent economic data showed a decline in initial jobless claims.

19. aug 2026, 19:27 UTC

Correlated Moves

Shares modestly higher, influenced by rise in iShares Biotechnology ETF.

18. aug 2026, 21:41 UTC

Bio-Techne Corp shares are higher in after-market trading, peaking early in the session and remaining near the upper end of their one-month trading range.

17. aug 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat amid broader market sentiment, with the Russell 2000 Index declining. Recent economic data has contributed to cautious conditions.

13. aug 2026, 19:16 UTC

Correlated Moves

News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5. aug 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4. aug 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3. aug 2026, 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31. juuli 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30. juuli 2026, 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29. juuli 2026, 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20. juuli 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Võrdlus sarnastega

Hinnamuutus

Bio-Techne Corp Prognoos

Hinnasiht

By TipRanks

0.87% tõus

12 kuu keskmine prognoos

Keskmine 73 USD 0.87%

Kõrge 73 USD

Madal 73 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Bio-Techne Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Bio-Techne Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

120 / 339 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.